{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:19:14Z","timestamp":1786119554341,"version":"build-2736575974"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1097\/ftd.0b013e3181f4d9c5","type":"journal-article","created":{"date-parts":[[2010,9,23]],"date-time":"2010-09-23T07:24:35Z","timestamp":1285226675000},"page":"680-687","source":"Crossref","is-referenced-by-count":18,"title":["Dasatinib, a Multikinase Inhibitor: Therapy, Safety, and Appropriate Management of Adverse Events"],"prefix":"10.1097","volume":"32","author":[{"given":"Sepideh","family":"Shayani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer Statistics, 2008.","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"R4-3-20210129","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia.","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"R5-3-20210129","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.","volume":"145","author":"Kantarjian","year":"2006","journal-title":"Ann Intern Med"},{"key":"R6-3-20210129","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia.","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"R7-3-20210129","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy.","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann Intern Med"},{"key":"R8-3-20210129","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0140-6736(95)92596-1","article-title":"UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response.","volume":"345","author":"Allan","year":"1995","journal-title":"Lancet"},{"key":"R9-3-20210129","first-page":"204","article-title":"A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients.","volume":"77","year":"1992","journal-title":"Haematologica"},{"key":"R10-3-20210129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7326\/0003-4819-104-2-155","article-title":"Marrow transplantation for the treatment of chronic myelogenous leukemia.","volume":"104","author":"Thomas","year":"1986","journal-title":"Ann Intern Med"},{"key":"R11-3-20210129","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1182\/blood.V72.6.1978.1978","article-title":"HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration.","volume":"72","author":"Martin","year":"1988","journal-title":"Blood"},{"key":"R12-3-20210129","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood.V84.6.2036.2036","article-title":"Marrow transplantation for chronic myeloid leukemia. A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide.","volume":"84","author":"Clift","year":"1994","journal-title":"Blood"},{"key":"R13-3-20210129","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"OBrien","year":"2003","journal-title":"N Engl J Med"},{"key":"R14-3-20210129","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"R15-3-20210129","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3324\/haematol.13045","article-title":"Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level.","volume":"93","author":"Brenner","year":"2008","journal-title":"Haematologica"},{"key":"R18-3-20210129","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"R19-3-20210129","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"R20-3-20210129","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"R21-3-20210129","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"R22-3-20210129","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","article-title":"Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood"},{"key":"R23-3-20210129","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of BCR-ABL inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.","volume":"65","author":"OHare","year":"2005","journal-title":"Cancer Res"},{"key":"R24-3-20210129","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1517\/14728214.11.4.651","article-title":"Emerging drugs in chronic myelogenous leukaemia.","volume":"11","author":"Bocchia","year":"2006","journal-title":"Expert Opin Emerg Drugs"},{"key":"R25-3-20210129","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor.","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"R26-3-20210129","doi-asserted-by":"crossref","first-page":"7906","DOI":"10.1038\/sj.onc.1208160","article-title":"Src family kinases, key regulators of signal transduction.","volume":"23","author":"Parsons","year":"2004","journal-title":"Oncogene"},{"key":"R28-3-20210129","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","article-title":"Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.","volume":"100","author":"Wu","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R30-3-20210129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00280-007-0478-8","article-title":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.","volume":"61","author":"Kamath","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"R32-3-20210129","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"R33-3-20210129","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-06-1112","article-title":"Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.","volume":"12","author":"Luo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R34-3-20210129","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.V84.6.1731.1731","article-title":"Tyrosine phosphorylation of CRKL in Philadelphia leukemia.","volume":"84","author":"ten Hoeve","year":"1994","journal-title":"Blood"},{"key":"R35-3-20210129","doi-asserted-by":"crossref","first-page":"22925","DOI":"10.1016\/S0021-9258(17)31596-X","article-title":"Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia.","volume":"269","author":"Oda","year":"1994","journal-title":"J Biol Chem"},{"key":"R36-3-20210129","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood.V84.9.2912.2912","article-title":"Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells.","volume":"84","author":"Nichols","year":"1994","journal-title":"Blood"},{"key":"R37-3-20210129","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"key":"R42-3-20210129","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib (100 mg once daily) preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"R44-3-20210129","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","article-title":"Phase III study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow up.","volume":"113","author":"Kantarjian","year":"2009","journal-title":"Blood"},{"key":"R46-3-20210129","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1124\/dmd.107.018267","article-title":"Metabolism and disposition of dasatinib after oral administration to humans.","volume":"36","author":"Christopher","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"R48-3-20210129","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"key":"R51-3-20210129","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.","volume":"25","author":"Quintas-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"key":"R52-3-20210129","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy.","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"issue":"Suppl 3","key":"R55-3-20210129","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.3816\/CLM.2008.s.003","article-title":"Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.","volume":"8","author":"Quintas-Cardama","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"R56-3-20210129","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"R57-3-20210129","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2008.07.015","article-title":"Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels.","volume":"33","author":"Forrest","year":"2009","journal-title":"Leuk Res"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0b013e3181f4d9c5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:33:38Z","timestamp":1786041218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-201012000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181f4d9c5","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}